ABBV vs INCY

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Incyte Corporation exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.01. The company is growing rapidly, with YoY revenue growth of 27.8% and earnings growth of 43.6%, while trading at a highly attractive PEG ratio of 0.34. Despite a bearish technical trend and insider selling, the current price of $95.72 sits significantly below the growth-based intrinsic value of $189.09. The combination of high ROE (29.87%) and strong liquidity makes this a compelling value-growth opportunity.